NEOMED-LABS / Pacific Biomarkers Acquires PAIRimmune

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

L2P Research Acquires METIS Research Laboratories

February 28, 2020

Biotechnology

L2P Research, LLC has acquired METIS Research Laboratories, a Ronkonkoma, New York-based preclinical CRO that provides radiotracer, radioligand binding, ADME/PK and QWBA services. The acquisition adds a GLP-compliant 5,000 sq. ft. facility and expands L2P's preclinical capabilities for pharma, biotech and academic customers.

MLM Medical Labs Acquires MD Biosciences, Inc.

October 27, 2020

Healthcare Services

MLM Medical Labs, a Great Point Partners portfolio company, has acquired MD Biosciences, Inc., an Oakdale, Minnesota-based provider of preclinical, translational and clinical-phase contract research services. The deal expands MLM's U.S. footprint and adds immunohistochemistry, preclinical research and histopathology capabilities to its global laboratory platform as part of an integration with recent U.S. additions such as CirQuest Labs.

Vertex Pharmaceuticals Acquires Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $65 per share (approximately $4.9 billion) in cash. The acquisition adds Alpine’s lead candidate povetacicept (ALPN‑303) and protein-engineering/immunotherapy capabilities to Vertex’s pipeline and is expected to close in Q2 2024, subject to customary conditions.

ImmunoPrecise Antibodies Acquires Belgian BioStrand, BioKey and BioClue

April 14, 2022

Biotechnology

ImmunoPrecise Antibodies Ltd. (IPA), through its subsidiary ImmunoPrecise Netherlands BV, completed the acquisition of BioStrand BV, BioKey BV and BioClue BV, a group of Belgian bioinformatics and biotech companies. The deal (approx. €20 million consideration plus up to €12 million earnout and a €6 million investment commitment) adds AI-driven multi-omics analytics and software capabilities to IPA's antibody discovery and biotherapeutics platform.

Nexelis to Acquire ImmunXperts

April 4, 2020

Healthcare Services

Nexelis, a portfolio company of Ampersand Capital Partners, has signed a definitive agreement to acquire ImmunXperts, a specialty immunogenicity and immuno‑oncology testing laboratory based in Gosselies, Belgium. The add-on deal will expand Nexelis' assay development and immunology testing capabilities and is expected to close by the end of March 2020.